Agency Information Collection Activities: Proposed Collection; Comment Request, 27450-27452 [2016-10705]
Download as PDF
27450
Federal Register / Vol. 81, No. 88 / Friday, May 6, 2016 / Notices
III. Registration Instructions
CMS’ Coverage and Analysis Group is
coordinating meeting registration. While
there is no registration fee, individuals
must register to attend. You may register
online at https://www.cms.gov/apps/
events/upcomingevents.asp?
strOrderBy=1&type=3 or by phone by
contacting the person listed in the FOR
FURTHER INFORMATION CONTACT section of
this notice by the deadline listed in the
DATES section of this notice. Please
provide your full name (as it appears on
your state-issued driver’s license),
address, organization, telephone
number(s), fax number, and email
address. You will receive a registration
confirmation with instructions for your
arrival at the CMS complex or you will
be notified that the seating capacity has
been reached.
identification (ID) cards. It prohibits
Federal agencies from accepting an
official driver’s license or ID card from
a state unless the Department of
Homeland Security determines that the
state meets these standards. Beginning
October 2015, photo IDs (such as a valid
driver’s license) issued by a state or
territory not in compliance with the
Real ID Act will not be accepted as
identification to enter Federal buildings.
Visitors from these states/territories will
need to provide alternative proof of
identification (such as a valid passport)
to gain entrance into CMS buildings.
The current list of states from which a
Federal agency may accept driver’s
licenses for an official purpose is found
at https://www.dhs.gov/real-idenforcement-brief. We recommend that
confirmed registrants arrive reasonably
early, but no earlier than 45 minutes
prior to the start of the meeting, to allow
additional time to clear security.
Security measures include the
following:
• Presentation of government-issued
photographic identification to the
Federal Protective Service or Guard
Service personnel.
• Inspection of vehicle’s interior and
exterior (this includes engine and trunk
inspection) at the entrance to the
grounds. Parking permits and
instructions will be issued after the
vehicle inspection.
• Inspection, via metal detector or
other applicable means, of all persons
entering the building. We note that all
items brought into CMS, whether
personal or for the purpose of
presentation or to support a
presentation, are subject to inspection.
We cannot assume responsibility for
coordinating the receipt, transfer,
transport, storage, set-up, safety, or
timely arrival of any personal
belongings or items used for
presentation or to support a
presentation.
Note: Individuals who are not
registered in advance will not be
permitted to enter the building and will
be unable to attend the meeting. The
public may not enter the building earlier
than 45 minutes prior to the convening
of the meeting.
All visitors must be escorted in areas
other than the lower and first floor
levels in the Central Building.
IV. Security, Building, and Parking
Guidelines
This meeting will be held in a federal
government building; therefore, federal
security measures are applicable. The
Real ID Act, enacted in 2005, establishes
minimum standards for the issuance of
state-issued driver’s licenses and
V. Collection of Information
This document does not impose
information collection requirements,
that is, reporting, recordkeeping or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
asabaliauskas on DSK3SPTVN1PROD with NOTICES
services being discussed. Speakers
presenting at the MEDCAC meeting
should include a full disclosure slide as
their second slide in their presentation
for financial interests (for example, type
of financial association—consultant,
research support, advisory board, and
an indication of level, such as minor
association <$10,000 or major
association >$10,000) as well as
intellectual conflicts of interest (for
example, involvement in a federal or
nonfederal advisory committee that has
discussed the issue) that may pertain in
any way to the subject of this meeting.
If you are representing an organization,
we require that you also disclose
conflict of interest information for that
organization. If you do not have a
PowerPoint presentation, you will need
to present the full disclosure
information requested previously at the
beginning of your statement to the
Committee.
The Committee will deliberate openly
on the topics under consideration.
Interested persons may observe the
deliberations, but the Committee will
not hear further comments during this
time except at the request of the
chairperson. The Committee will also
allow a 15-minute unscheduled open
public session for any attendee to
address issues specific to the topics
under consideration. At the conclusion
of the day, the members will vote and
the Committee will make its
recommendation(s) to CMS.
VerDate Sep<11>2014
17:20 May 05, 2016
Jkt 238001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35).
Authority: 5 U.S.C. App. 2, section 10(a).
Dated: April 27, 2016.
Kate Goodrich,
Director, Center for Clinical Standards and
Quality, Centers for Medicare & Medicaid
Services.
[FR Doc. 2016–10716 Filed 5–5–16; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10185 and CMS–
10328]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, HHS.
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995 (the
PRA), federal agencies are require; to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
any of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
DATES: Comments must be received by
July 5, 2016.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
SUMMARY:
E:\FR\FM\06MYN1.SGM
06MYN1
Federal Register / Vol. 81, No. 88 / Friday, May 6, 2016 / Notices
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number __, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, you may make your request
using one of following:
1. Access CMS’ Web site address at
https://www.cms.hhs.gov/
PaperworkReductionActof1995.
2. Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov.
3. Call the Reports Clearance Office at
(410) 786–1326.
FOR FURTHER INFORMATION CONTACT:
Reports Clearance Office at (410) 786–
1326.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–10185 Medicare Part D
Reporting Requirements and
Supporting Regulations
asabaliauskas on DSK3SPTVN1PROD with NOTICES
CMS–10328 Medicare Self-Referral
Disclosure Protocol
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
VerDate Sep<11>2014
17:20 May 05, 2016
Jkt 238001
requirement, CMS is publishing this
notice.
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Medicare Part D
Reporting Requirements and Supporting
Regulations; Use: Data collected via
Medicare Part D Reporting
Requirements will be an integral
resource for oversight, monitoring,
compliance and auditing activities
necessary to ensure quality provision of
the Medicare Prescription Drug Benefit
to beneficiaries. For all reporting
sections, data are reported electronically
to CMS. Each reporting section is
reported at one of the following levels:
Contract (data should be entered at the
H#, S#, R#, or E# level) or Plan (data
should be entered at the Plan Benefit
Package (PBP level, e.g., Plan 001 for
contract H#, R#, S#, or E). Sponsors
should retain documentation and data
records related to their data
submissions. Data will be validated,
analyzed, and utilized for trend
reporting by the Division of Clinical and
Operational Performance (DCOP) within
the Medicare Drug Benefit and C & D
Data Group. If outliers or other data
anomalies are detected, DCOP will work
in collaboration with other Divisions
within CMS for follow-up and
resolution. For CY2017 Reporting
Requirements, the following 7 reporting
sections will be reported and collected
at the Contract-level or Plan-level:
Enrollment and Disenrollment, Retail,
Home Infusion, and Long-Term Care
Pharmacy Access, Medication Therapy
Management (MTM) Programs,
Grievances, Improving Drug Utilization
Review Controls, Coverage
Determinations and Redeterminations,
and Employer/Union Sponsored
Sponsors. Form Number: CMS–10185
(OMB control number: 0938–0992);
Frequency: Annually and semiannually; Affected Public: Private sector
(Business or other for-profits); Number
of Respondents: 561; Total Annual
Responses: 11,438; Total Annual Hours:
14,750. (For policy questions regarding
this collection contact Chanelle Jones at
410–786–8008).
2. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Medicare SelfReferral Disclosure Protocol; Use: The
Affordable Care Act (‘‘ACA’’) was
enacted on March 23, 2010. Section
6409 of the ACA requires the Secretary
of the Department of Health and Human
Services (the ‘‘Secretary’’), in
cooperation with the Office of Inspector
General of the Department of Health and
Human Services, to establish a Medicare
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
27451
self-referral disclosure protocol
(‘‘SRDP’’). The SRDP enables providers
of services and suppliers to self-disclose
actual or potential violations of the
physician self-referral statute, section
1877 of the Social Security Act (the
‘‘Act’’). Section 6409(b) of the ACA
gives the Secretary the authority to
reduce the amount due and owing for
all violations of section 1877 of the Act.
In establishing the amount by which an
overpayment may be reduced, the
Secretary may consider: The nature and
extent of the improper or illegal
practice; the timeliness of the selfdisclosure; the cooperation in providing
additional information related to the
disclosure; and such other factors as the
Secretary considers appropriate.
In accordance with the ACA, CMS
established the SRDP on September 23,
2010, and information concerning how
to disclose an actual or potential
violation of section 1877 of the Act was
posted on the CMS Web site. The most
recent approval of this information
collection request (‘‘ICR’’) was issued by
the Office of Management and Budget
on August 26, 2014.
We are now seeking approval to revise
the currently approved ICR. Under the
currently approved collection, a party
must provide a financial analysis of
overpayments arising from actual or
potential violations of section 1877 of
the Act based on a 4-year lookback
period. On February 12, 2016, CMS
published a final rule on the reporting
and returning of overpayments. See
CMS–6037–F, Medicare Program;
Reporting and Returning of
Overpayments, 81 FR 7654 (Feb. 12,
2016) (the ‘‘final overpayment rule’’).
The final overpayment rule establishes
a 6-year lookback period for reporting
and returning overpayments. We are
revising the information collection for
the SRDP to reflect the 6-year lookback
period established by the final
overpayment rule. The re vision is
necessary to ensure that parties
submitting self-disclosures to the SRDP
report overpayments for the entire 6year lookback period. The 6-year
lookback period applies only to
submissions to the SRDP received on or
after March 14, 2016, the effective date
of the final overpayment rule; parties
submitting self-disclosures to the SRDP
prior to March 14, 2016 need only
provide a financial analysis of potential
overpayments based on a 4-year
lookback period.
We are also taking the opportunity to
streamline and simplify the SRDP by
issuing a required form for SRDP
submissions. The SRDP Form will
reduce the burden on disclosing parties
by reducing the amount of information
E:\FR\FM\06MYN1.SGM
06MYN1
27452
Federal Register / Vol. 81, No. 88 / Friday, May 6, 2016 / Notices
that is required for submissions to the
SRDP and providing a streamlined and
standardized format for the presentation
of the required information. Form
Number: CMS–10328 (OMB control
number: 0938–1106); Frequency:
Annually and semi-annually; Affected
Public: Private sector (Business or other
for-profits and Not-for-profits); Number
of Respondents: 200; Total Annual
Responses: 200; Total Annual Hours:
5,000. (For policy questions regarding
this collection contact Matt Edgar at
410–786–0698.)
Dated: May 3, 2016.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2016–10705 Filed 5–5–16; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1687]
Advisory Committee; Pharmacy
Compounding Advisory Committee,
Renewal
AGENCY:
Food and Drug Administration,
HHS.
Notice; renewal of advisory
committee.
ACTION:
The Food and Drug
Administration (FDA) is announcing the
renewal of the Pharmacy Compounding
Advisory Committee by the
Commissioner of Food and Drugs (the
Commissioner). The Commissioner has
determined that it is in the public
interest to renew the Pharmacy
Compounding Advisory Committee for
an additional 2 years beyond the charter
expiration date. The new charter will be
in effect until April 25, 2018.
DATES: Authority for the Pharmacy
Compounding Advisory Committee will
expire on April 25, 2016, unless the
Commissioner formally determines that
renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT:
Cindy Hong, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001,
PCAC@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to 41 CFR 102–3.65 and approval by the
Department of Health and Human
Services pursuant to 45 CFR part 11 and
by the General Services Administration,
FDA is announcing the renewal of the
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:20 May 05, 2016
Jkt 238001
Pharmacy Compounding Advisory
Committee. The committee is a
discretionary Federal advisory
committee established to provide advice
to the Commissioner. The Pharmacy
Compounding Advisory Committee
advises the Commissioner or designee
in discharging responsibilities as they
relate to compounded drugs for human
use and, as required, any other product
for which the Food and Drug
Administration has regulatory
responsibility.
The Committee shall provide advice
on scientific, technical, and medical
issues concerning drug compounding
under sections 503A and 503B of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 353a) and (21 U.S.C. 353b),
and, as required, any other product for
which the Food and Drug
Administration has regulatory
responsibility, and make appropriate
recommendations to the Commissioner
of Food and Drugs.
The Committee shall consist of a core
of 12 voting members including the
Chair. Members and the Chair are
selected by the Commissioner or
designee from among authorities
knowledgeable in the fields of
pharmaceutical compounding,
pharmaceutical manufacturing,
pharmacy, medicine, and related
specialties. These members will include
representatives from the National
Association of Boards of Pharmacy, the
United States Pharmacopeia,
pharmacists with current experience
and expertise in compounding,
physicians with background and
knowledge in compounding, and patient
and public health advocacy
organizations. Members will be invited
to serve for overlapping terms of up to
4 years. Almost all non-Federal
members of this committee serve as
Special Government Employees. The
core of voting members may include one
or more technically qualified members,
selected by the Commissioner or
designee, who are identified with
consumer interests and are
recommended by either a consortium of
consumer-oriented organizations or
other interested persons. In addition to
the voting members, the Committee may
include one or more non-voting
members who are identified with
industry interests.
Further information regarding the
most recent charter and other
information can be found at https://
www.fda.gov/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/
PharmacyCompoundingAdvisory
Committee/ucm381305.htm or by
contacting the Designated Federal
Officer (see FOR FURTHER INFORMATION
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
CONTACT).
In light of the fact that no
change has been made to the committee
name or description of duties, no
amendment will be made to 21 CFR
14.100.
This document is issued under the
Federal Advisory Committee Act (5
U.S.C. app.). For general information
related to FDA advisory committees,
please visit us at https://www.fda.gov/
AdvisoryCommittees/default.htm.
Dated: April 29, 2016.
Jill Hartzler Warner,
Associate Commissioner for Special Medical
Programs.
[FR Doc. 2016–10585 Filed 5–5–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects (section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995), the
Health Resources and Services
Administration (HRSA) announces
plans to submit an Information
Collection Request (ICR), described
below, to the Office of Management and
Budget (OMB). Prior to submitting the
ICR to OMB, HRSA seeks comments
from the public regarding the burden
estimate, below, or any other aspect of
the ICR.
DATES: Comments on this Information
Collection Request must be received no
later than July 5, 2016.
ADDRESSES: Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 14N–39, Parklawn
Building, 5600 Fishers Lane, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call the HRSA Information Collection
Clearance Officer at (301) 443–1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
information request collection title for
reference.
SUMMARY:
E:\FR\FM\06MYN1.SGM
06MYN1
Agencies
[Federal Register Volume 81, Number 88 (Friday, May 6, 2016)]
[Notices]
[Pages 27450-27452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-10705]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifier: CMS-10185 and CMS-10328]
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare & Medicaid Services, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is
announcing an opportunity for the public to comment on CMS' intention
to collect information from the public. Under the Paperwork Reduction
Act of 1995 (the PRA), federal agencies are require; to publish notice
in the Federal Register concerning each proposed collection of
information (including each proposed extension or reinstatement of an
existing collection of information) and to allow 60 days for public
comment on the proposed action. Interested persons are invited to send
comments regarding our burden estimates or any other aspect of this
collection of information, including any of the following subjects: (1)
The necessity and utility of the proposed information collection for
the proper performance of the agency's functions; (2) the accuracy of
the estimated burden; (3) ways to enhance the quality, utility, and
clarity of the information to be collected; and (4) the use of
automated collection techniques or other forms of information
technology to minimize the information collection burden.
DATES: Comments must be received by July 5, 2016.
ADDRESSES: When commenting, please reference the document identifier or
OMB control number. To be assured consideration, comments and
recommendations must be submitted in any one of the following ways:
1. Electronically. You may send your comments electronically to
https://www.regulations.gov. Follow the
[[Page 27451]]
instructions for ``Comment or Submission'' or ``More Search Options''
to find the information collection document(s) that are accepting
comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: Document Identifier/OMB
Control Number __, Room C4-26-05, 7500 Security Boulevard, Baltimore,
Maryland 21244-1850.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, you may make
your request using one of following:
1. Access CMS' Web site address at https://www.cms.hhs.gov/PaperworkReductionActof1995.
2. Email your request, including your address, phone number, OMB
number, and CMS document identifier, to Paperwork@cms.hhs.gov.
3. Call the Reports Clearance Office at (410) 786-1326.
FOR FURTHER INFORMATION CONTACT: Reports Clearance Office at (410) 786-
1326.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the use and burden associated
with the following information collections. More detailed information
can be found in each collection's supporting statement and associated
materials (see ADDRESSES).
CMS-10185 Medicare Part D Reporting Requirements and Supporting
Regulations
CMS-10328 Medicare Self-Referral Disclosure Protocol
Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain
approval from the Office of Management and Budget (OMB) for each
collection of information they conduct or sponsor. The term
``collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA requires federal agencies
to publish a 60-day notice in the Federal Register concerning each
proposed collection of information, including each proposed extension
or reinstatement of an existing collection of information, before
submitting the collection to OMB for approval. To comply with this
requirement, CMS is publishing this notice.
1. Type of Information Collection Request: Revision of a currently
approved collection; Title of Information Collection: Medicare Part D
Reporting Requirements and Supporting Regulations; Use: Data collected
via Medicare Part D Reporting Requirements will be an integral resource
for oversight, monitoring, compliance and auditing activities necessary
to ensure quality provision of the Medicare Prescription Drug Benefit
to beneficiaries. For all reporting sections, data are reported
electronically to CMS. Each reporting section is reported at one of the
following levels: Contract (data should be entered at the H#, S#, R#,
or E# level) or Plan (data should be entered at the Plan Benefit
Package (PBP level, e.g., Plan 001 for contract H#, R#, S#, or E).
Sponsors should retain documentation and data records related to their
data submissions. Data will be validated, analyzed, and utilized for
trend reporting by the Division of Clinical and Operational Performance
(DCOP) within the Medicare Drug Benefit and C & D Data Group. If
outliers or other data anomalies are detected, DCOP will work in
collaboration with other Divisions within CMS for follow-up and
resolution. For CY2017 Reporting Requirements, the following 7
reporting sections will be reported and collected at the Contract-level
or Plan-level: Enrollment and Disenrollment, Retail, Home Infusion, and
Long-Term Care Pharmacy Access, Medication Therapy Management (MTM)
Programs, Grievances, Improving Drug Utilization Review Controls,
Coverage Determinations and Redeterminations, and Employer/Union
Sponsored Sponsors. Form Number: CMS-10185 (OMB control number: 0938-
0992); Frequency: Annually and semi-annually; Affected Public: Private
sector (Business or other for-profits); Number of Respondents: 561;
Total Annual Responses: 11,438; Total Annual Hours: 14,750. (For policy
questions regarding this collection contact Chanelle Jones at 410-786-
8008).
2. Type of Information Collection Request: Revision of a currently
approved collection; Title of Information Collection: Medicare Self-
Referral Disclosure Protocol; Use: The Affordable Care Act (``ACA'')
was enacted on March 23, 2010. Section 6409 of the ACA requires the
Secretary of the Department of Health and Human Services (the
``Secretary''), in cooperation with the Office of Inspector General of
the Department of Health and Human Services, to establish a Medicare
self-referral disclosure protocol (``SRDP''). The SRDP enables
providers of services and suppliers to self-disclose actual or
potential violations of the physician self-referral statute, section
1877 of the Social Security Act (the ``Act''). Section 6409(b) of the
ACA gives the Secretary the authority to reduce the amount due and
owing for all violations of section 1877 of the Act. In establishing
the amount by which an overpayment may be reduced, the Secretary may
consider: The nature and extent of the improper or illegal practice;
the timeliness of the self-disclosure; the cooperation in providing
additional information related to the disclosure; and such other
factors as the Secretary considers appropriate.
In accordance with the ACA, CMS established the SRDP on September
23, 2010, and information concerning how to disclose an actual or
potential violation of section 1877 of the Act was posted on the CMS
Web site. The most recent approval of this information collection
request (``ICR'') was issued by the Office of Management and Budget on
August 26, 2014.
We are now seeking approval to revise the currently approved ICR.
Under the currently approved collection, a party must provide a
financial analysis of overpayments arising from actual or potential
violations of section 1877 of the Act based on a 4-year lookback
period. On February 12, 2016, CMS published a final rule on the
reporting and returning of overpayments. See CMS-6037-F, Medicare
Program; Reporting and Returning of Overpayments, 81 FR 7654 (Feb. 12,
2016) (the ``final overpayment rule''). The final overpayment rule
establishes a 6-year lookback period for reporting and returning
overpayments. We are revising the information collection for the SRDP
to reflect the 6-year lookback period established by the final
overpayment rule. The re vision is necessary to ensure that parties
submitting self-disclosures to the SRDP report overpayments for the
entire 6-year lookback period. The 6-year lookback period applies only
to submissions to the SRDP received on or after March 14, 2016, the
effective date of the final overpayment rule; parties submitting self-
disclosures to the SRDP prior to March 14, 2016 need only provide a
financial analysis of potential overpayments based on a 4-year lookback
period.
We are also taking the opportunity to streamline and simplify the
SRDP by issuing a required form for SRDP submissions. The SRDP Form
will reduce the burden on disclosing parties by reducing the amount of
information
[[Page 27452]]
that is required for submissions to the SRDP and providing a
streamlined and standardized format for the presentation of the
required information. Form Number: CMS-10328 (OMB control number: 0938-
1106); Frequency: Annually and semi-annually; Affected Public: Private
sector (Business or other for-profits and Not-for-profits); Number of
Respondents: 200; Total Annual Responses: 200; Total Annual Hours:
5,000. (For policy questions regarding this collection contact Matt
Edgar at 410-786-0698.)
Dated: May 3, 2016.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 2016-10705 Filed 5-5-16; 8:45 am]
BILLING CODE 4120-01-P